Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Patients with schizophrenia are much more likely to be engaged in smoking and other addictive
behaviors, possibly related to biochemical abnormalities in the reward center of the brain.
The primary purpose of the present study is to investigate whether switching patients with
schizophrenia to a new atypical antipsychotic, aripiprazole, a drug with a novel mechanism of
action, will have an impact on smoking behavior.